What Does Avadel Pharmaceuticals ($AVDL) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks & Headquarters Summary
A specialty pharmaceutical company focused on sleep disorders. LUMRYZ narcolepsy treatment. Q3 2025 55% YoY growth, 3,400 patients. Acquisition by Alkermes (Q1 2026).
Subscribe🏢 What kind of company is Avadel Pharmaceuticals?
Avadel Pharmaceuticals plc (AVDL) is a specialty pharmaceutical company focused on sleep-disorder treatments. Its lead product, LUMRYZ (oxybate), treats cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy. LUMRYZ has been granted 7-year Orphan Drug Exclusivity by the FDA for adult and pediatric narcolepsy patients. The company is achieving rapid revenue growth and patient expansion in 2025, and will join a large pharmaceutical group through its acquisition by Alkermes in January 2026.
How does it make money?| Business Segment | Revenue Share | Description |
|---|---|---|
| LUMRYZ (Narcolepsy) | Approximately 95% | Oxybate-based cataplexy treatment; sales growing rapidly |
| Other Products / Licensing Fees | Approximately 5% | Pipeline development and other revenue |
Q3 2025 quarterly revenue came in at $248.5M, representing a change of +79.9% YoY. LUMRYZ net revenue grew 55% YoY, delivering strong growth. Quarterly patient count reached 3,400, up 48% YoY, with patient enrollment momentum continuing. FY2025 revenue guidance has been raised, and the year-end patient count target has also been strengthened.
📐 Market Capitalization and Company Scale
Market capitalization is $2.1B, with 188 people employees.
As a specialty pharmaceutical company focused on sleep disorders, Avadel is delivering high-growth LUMRYZ sales and sustained patient enrollment. While narcolepsy is a rare disease, improving diagnostic and treatment awareness is broadening the opportunity to enroll new patients. The company is strengthening its pipeline with REVITALYZ (Phase 3 in idiopathic hypersomnia) and Valiloxybate (a new compound in-license). The Alkermes acquisition will combine the global resources and distribution network of a large pharmaceutical company.
📈 Avadel Pharmaceuticals Outlook and Price Action
1-Year Price Performance
Analyst Consensus
52-Week Price RangeDemand for sleep-disorder treatments—especially for the rare disease narcolepsy—is a structurally growing market, driven by improved diagnostics and rising medical awareness. Avadel has built market leadership through LUMRYZ's exclusive treatment status and strong clinical results. However, competitive drug launches, changes in insurance reimbursement decisions, and regulatory risk are factors to watch. The Alkermes acquisition (Q1 2026) signals expanded global reach and accelerated development of the additional pipeline.
⚔️ Key Strengths and Risks
LUMRYZ's strong growth and rare-disease market tailwinds are key strengths, but regulatory risk and competitive drug launches are the main challenges.
💪 Key Strengths
⚠️ Key Risks
Competitors in the sleep-disorder and narcolepsy treatment space include Jazz Pharmaceuticals (Xyrem/Wakix oxybate), Biohaven Pharmaceuticals, and several new entrants. Larger pharmaceutical companies are also moving into narcolepsy drug development. Avadel's strengths lie in LUMRYZ's strong clinical data and Orphan Drug Exclusivity.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 JAZZ | Jazz Pharmaceuticals plc | $240.07 | -2.7% | $15.6B | 16.6 | 3.2 | 22.11% | - |
 BHVN | Biohaven Ltd | $14.72 | -6.2% | $2.2B | - | 181.9 | -799.46% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | $269.12 | -2.2% | $648.6B | 31.2 | 7.6 | 25.74% | 2% |
| PFE | Pfizer Inc | $27.79 | -2.3% | $158.4B | 36.8 | 1.9 | 4.99% | 6.2% |
| ABBV | Abbvie Inc | $248.78 | -3.0% | $439.6B | 70.3 | - | 15221.82% | 2.76% |
| MRK | Merck & Co Inc | $148.46 | -1.2% | $366.3B | 118.7 | 8.7 | 6.98% | 2.3% |
✅ Investor Checkpoints
Avadel Pharmaceuticals is a specialty sleep-disorder pharmaceutical company delivering strong LUMRYZ growth. Q3 2025's strong revenue growth and 3,400 patients confirm robust market demand. The Alkermes acquisition (Q1 2026) signals global expansion and accelerated pipeline development, which will be a key foundation for future growth.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 📈 LUMRYZ Sales Trend | Quarterly revenue growth and market-share expansion | Whether FY2025 target ($255–265M) is achieved |
| 👥 Patient Base Expansion | Quarterly new patient enrollment and treatment persistence | Year-end target of 3,400–3,600 patients |
| 💊 Pipeline Progress | REVITALYZ Phase 3 progress and Valiloxybate development | Potential for new indication expansion |
| 🤝 Alkermes Acquisition Progress | Approval of the deal and integration timeline (Q1 2026) | Synergy realization post-closing |
Regulatory risks (FDA approval withdrawal, safety issues), market entry by competing drugs, reimbursement restrictions from insurers, and integration risk with Alkermes are the primary concerns. Slowing growth is also possible due to the limited size of the rare-disease market.
Avadel Pharmaceuticals is a specialty narcolepsy pharmaceutical company that has delivered strong commercial results with LUMRYZ. The robust Q3 2025 growth and 3,400 patients confirm strong market demand. The Alkermes acquisition (Q1 2026) will enable access to global resources and pipeline expansion, and the success of REVITALYZ and other new pipeline programs is expected to be central to long-term growth.
Check Avadel Pharmaceuticals' real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free